Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HCW BiologicsHCWB -1.96%37 Cash Ratio is 0.06 as of Mar. 2026, which is 97% below its 10-year median of 2.07. GuruFocus rates HCWB with a GF Score™ of 37/100 and a GF Value™ of $43.75 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,385 Biotechnology companies, HCW Biologics ranks worse than 96.39% on this metric.
HCW Biologics has a Cash Ratio of 0.06. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for HCW Biologics's Cash Ratio or its related term are showing as below:
HCWB'
s Cash Ratio Range Over the Past 10 Years
Min: 0.03 Med: 2.07 Max: 28.31
Current: 0.06
During the past 7 years, HCW Biologics's highest Cash Ratio was 28.31. The lowest was 0.03. And the median was 2.07.
HCWB's Cash Ratio is ranked worse than 96.39% of 1385
companies
in the Biotechnology industry
Industry Median: 2.95
vs HCWB: 0.06
HCW Biologics (NAS:HCWB) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
HCW Biologics Cash Ratio Related Terms
HCW Biologics Cash Ratio Historical Data
* Premium members only.
The historical data trend for HCW Biologics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HCW Biologics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where HCW Biologics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics (HCWB) has a Cash Ratio of 0.06 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on HCW Biologics and its competitors. This is 97% below median its historical median of 2.07. Over the past decade, HCW Biologics' Cash Ratio has ranged from 0.03 to 28.31. According to the industry distribution chart, HCW Biologics ranks #1335 out of 1385 companies in the Biotechnology industry, placing it in the top 96.4%.
Is HCW Biologics' Cash Ratio too high?
HCW Biologics' current Cash Ratio of 0.06 is 97% below median its 10-year median of 2.07. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 28.31. The Biotechnology industry median Cash Ratio is 2.95. HCW Biologics' value of 0.06 is 98% below this industry median. Based on the distribution chart, HCW Biologics ranks #1335 out of 1385 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, HCW Biologics has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' Cash Ratio compare to KAPA and IMNN?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #1335 out of 1385 companies for Cash Ratio. This places HCW Biologics in the lower half of its industry. The industry median Cash Ratio is 2.95. HCW Biologics' value of 0.06 is 98% below this benchmark. Historically, HCW Biologics' own Cash Ratio has ranged from 0.03 to 28.31 over the past decade. While the company's 10-year median is 2.07 vs. the industry median of 2.95, HCW Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.95, based on 1,385 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HCW Biologics's current Cash Ratio of 0.06 is 98% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on HCW Biologics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCW Biologics's current Cash Ratio is 0.06, which is 97% below median its own 10-year median of 2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $43.75, compared to a current price of $4.00 — trading 90.9% below its estimated fair value. The current Cash Ratio is 0.06, which is 97% below median its 10-year median of 2.07 and 98% below the Biotechnology industry median of 2.95. HCW Biologics' overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For HCW Biologics (HCWB), the current Cash Ratio is 0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $4.00 is trading 90.9% below its estimated GF Value™ of $43.75.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
Cash Ratio: 0.06 (97% below median its 10-year median of 2.07)
GF Value™: $43.75 vs. price of $4.00 (90.9% below fair value)
Industry Position: 98% below the Biotechnology median (#1335 of 1385)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
37GF Score
Get the complete analysis for HCWB
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
